Eton Pharmaceuticals Inc (ETON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Eton Pharmaceuticals Inc (ETON) P/E Ratio & Valuation History
Eton Pharmaceuticals (ETON) trades at 36.7x trailing earnings and 13.0x sales. Its P/S of 13.0x is above its 5-year median of 6.2x. Its forward P/E is 20.8x. The median P/E across 10 similar companies is 10.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 76.4% higher over the next year. Its free cash flow yield is 2.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 36.7x |
| Forward P/E | 20.8x |
| Price to sales | 13.0x |
| Price to book | 21.1x |
| EV/EBITDA | 38.8x |
| Price to FCF | 47.9x |
| EV/FCF | 47.1x |
| PEG | N/A |
| FCF yield | 2.1% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 13.0x | 6.2x | N/A |
| P/B | 21.1x | 8.7x | N/A |
Valuation History
Over the 5 of the 8 year ends shown that have a P/S, its P/S ranged from 3.4x in 2022 to 132.9x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $16.91 | 241.6x | 5.7x | 17.4x |
| 2024 | $13.32 | N/A | 8.8x | 14.3x |
| 2023 | $4.38 | N/A | N/A | 7.3x |
| 2022 | $2.82 | N/A | 3.4x | 5.5x |
| 2021 | $4.29 | N/A | 4.9x | 6.3x |
| 2020 | $8.13 | N/A | N/A | 12.4x |
| 2019 | $7.20 | N/A | 132.9x | 12.2x |
| 2018 | $6.12 | N/A | N/A | 2.7x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ETON
What is ETON's forward P/E ratio?
Eton Pharmaceuticals has a forward P/E ratio of 20.8x.
Is ETON stock overvalued?
GNG's valuation label for ETON is Overvalued. Its P/E of 36.7x compares with a median of 10.5x across 10 similar companies.
What is ETON's price to sales ratio?
Eton Pharmaceuticals has a price to sales ratio of 13.0x.
ETON pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors